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Basal cell carcinoma (BCC) incidence rates are increa-
sing worldwide. This study’s objective was to estimate 
the occurrence of BCC in the Netherlands in terms of 
incidence and prevalence. Data on first primary carcino-
mas were retrieved from the Eindhoven Cancer Registry 
and extrapolated to the Dutch population. Extrapolated 
data showed a total of 444,131, histologically confirmed 
cases in the Netherlands between 1973 and 2008. During 
this period, age-adjusted incidence rates (European 
Standard Population) increased approximately three-
fold from 40 to 148 per 100,000 in males and from 34 
to 141 in females. Lifetime risk of BCC was 1 in 5–6 for 
Dutch citizens. Disease prevalence in the Netherlands 
was 1.4% and almost four times higher than this (5.4%) 
in the oldest age group (age 65 years or more). Predic-
tions of future trends showed no signs of a plateau in 
the number of cases. These estimates should urge Dutch 
policymakers to provide solutions for the growing group 
of patients with BCC. Key words: basal cell carcinoma; 
epidemiology; incidence; prevalence.
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Non-melanoma skin cancer (NMSC) is by far the most 
common cancer in Caucasians and numerous studies 
have shown that incidence rates, especially for basal cell 
carcinomas (BCC), are increasing worldwide (1–5). The 
burden of BCC is becoming an increasingly important 
public health issue, because of the rapidly increasing 
numbers of patients with a history of BCC, the total 
number of BCC patients and the costs of their treatment 
and follow-up (4, 6, 7). 
A Dutch population-based survey revealed increases in 
European Standardized BCC incidence rates between 1973 
and 2000, from 40 to 92 per 100,000 in men and 34 to 79 
per 100,000 in women (6). Forecasts of BCC incidence in 
the Netherlands, based on data from the Eindhoven Cancer 
Registry (ECR) for the years 1989–2000, estimated annual 
incidence rates of 122 and 119 per 100,000 for males and 
females, respectively, in 2015 (7). 
The main causes of this continuous rise in BCC inci-
dence are the effects of altered UV exposure patterns, 
population aging, the increasing number of people with 
a prior skin cancer diagnosis, who are at high risk of 
developing subsequent skin cancers, and an increased 
awareness of skin cancer among patients and physicians 
(i.e., detection bias). An estimated 40% of patients with 
a first BCC will develop subsequent tumours in the next 
5 years (8, 9).
Whilst BCC causes very low mortality, it is associated 
with considerable functional and cosmetic morbidity as 
most lesions are located on the face and are typically 
treated surgically. There is currently a shortage of der-
matologists in the Netherlands (about 475 full- and part-
time specialists for a population of 16.4 million) and 
the rising incidence of BCC is putting a heavy burden 
on the already limited healthcare system in terms of 
diagnosis, treatment and especially follow-up, which 
represents a substantial proportion of dermatologists’ 
workload (10). Earlier predictions for 2015 (made in 
2004), warned Dutch policy makers about the need 
to provide solutions in order to continue to be able to 
provide sufficient management for the already large 
and continuously growing group of BCC patients (7). 
Direct treatment-related costs depend on the number of 
treated lesions and selected therapies. In order to make 
correct workload and cost estimates, we need recent, 
accurate estimates of the scale of the problem with BCC 
in the Netherlands (which are currently not up-to-date), 
including estimates of the prevalence of BCC (which 
are lacking). 
The objective of this study was to reliably estimate 
the occurrence of BCC in the Netherlands, in terms of 
incidence and prevalence, using up-to-date data from 
the ECR. Using BCC data from the period 1973 to 2008, 
we were the first to estimate the 19-year prevalence of 
first, histologically proven BCC in the Netherlands. 
Additionally, new predictions were made for incidence 
rates and patient numbers in the Netherlands for the 
years 2010, 2015 and 2020. 
METHODS
Data
Data were obtained from the ECR, which is part of the Nether-
lands Cancer Registry, located at the only population-based 
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cancer registry in the Netherlands that routinely registers the 
first, histologically proven BCC cases, using the national patho-
logy laboratories network (PALgA) as a signalling source (6). 
All individuals with a histologically proven first primary BCC, 
diagnosed between 1973 and 2008, were included. The ECR 
also registers data concerning BCC body location. During the 
study period (January 1, 1973 to January 1, 2009) the popula-
tion size of the ECR catchment region increased from 591,916 
to 2,252,757, mainly due to expansion of the registry area 
(11). Age-adjustment was performed by direct standardisation 
according to European Standardized Rates (ESR) and World 
Standardized Rates (WSR), respectively. Annual incidence 
rates were computed per 100,000 person-years for each sex and 
calculated as 5-year moving means, except for annual incidence 
by site (3-year moving means) (6). 
Statistical analysis
The incidence of the first primary, histologically confirmed 
BCC was calculated. Numbers of BCC cases, subdivided by 
sex and into eighteen 5-year age groups (0–4, 5–9, 10–14, 
etc.), were divided by the number of inhabitants in the ECR 
catchment area in these same categories. Sex- and age-specific 
incidence rates were multiplied by the population size of these 
specific categories in the Netherlands in the year concerned to 
provide an estimate of the number of first primary BCC patients 
in the country as a whole. Population sizes were obtained from 
Statistics Netherlands and estimated on the first of January of 
the relevant year (12). 
The cumulative incidence rates at age 84 were calculated 
as the sum of the age-specific incidence rates for ages 0–84, 
multiplied by the width of the age groups (5 years). Cumulative 
risks were calculated from the cumulative incidence rates using 
the following formula:
Cumulative risk = 100 × (1-exp (cumulative rate/100)). 
To calculate the prevalence of BCC in the ECR catchment area 
between 1990 and 2008, we retrieved data of the vital status of 
all patients diagnosed with a BCC since 1990 and still alive on 
the first of January 2009, a method that was previously used in 
reports of cancer prevalence in the Netherlands (13). 
Predicted numbers of BCC cases in the Netherlands in 2010, 
2015 and 2020 were estimated by first predicting the incidence 
rates on the basis of observed rates for the period 2000–2008, 
and then multiplying these rates by the population forecasts 
for these periods, derived from Statistics Netherlands. The 
statistical models used have been described before (7, 14). The 
following best-fitted model was employed: 
Emit = αi + βi × t.
Analyses were performed using SPSS for Windows version 
15.0 (SPSS inc., Chicago, IL, USA) and STATA statistical soft-
ware version 10.0 (College Station, TX, USA).  p-values were 
calculated in two-sided tests and were considered statistically 
significant if less than 0.05. 
RESULTS
Incidence data from the Eindhoven Cancer Registry 
A total of 48,221 first primary BCC cases were diagno-
sed in the ECR catchment area between January 1, 1973 
and December 31 2008. Of these, 23,918 (49.6%) were 
men and 24,303 (50.4%) women. The age-adjusted 
ESR for BCC increased from 40 to 148 per 100,000 
for males and from 34 to 141 per 100,000 for females 
(Table I and Fig. 1A). The age-adjusted incidence 
rates calculated using the WSR rose from 27 to 101 
per 100,000 for males and from 22 to 101 per 100,000 
for females (Table I). During this 25-year period, the 
cumulative incidence rate for BCC development at age 
84 increased from 5.0% to 19.3% in males and from 
5.2% to 16.3% in females (Table I). This implies that, 
in 2008, 1 in 5 men and 1 in 6 women had developed 
a BCC before the age of 85.
We plotted BCC incidence rates stratified by age 
and sex for the most recent year (2008) (Fig. 1B). The 
results showed that, up to the age of 60, women had 
higher BCC incidence rates than men, with this trend 
being reversed in subjects over the age of 60. 
Incidence data extrapolated to the Netherlands
We assumed the age-specific ESR of the ECR region 
to be representative of the Netherlands as a whole. 
Extrapolating the age-specific incidence rates to the 
entire Dutch population estimated the diagnosis of a 
total of 444,131 primary BCC cases between 1973 and 
2008. Of these cases, 220,758 were men and 223,373 
Table I. First primary, histologically confirmed basal cell carcinoma 
(BCC) cases extrapolated to the population of the Netherlands
 Men Women
 1973 2008 1973 2008
ESR      40      148      34      141
WSR      27      101      22      101
Cumulative risk*, %      5.0     19.3     5.2     16.3
Total number of BCC cases 1,946 13,891 2,233 15,094
*Calculated at age 84 years. 
ESR: European Standard Rate; WSR: World Standard Rate; both 
expressed per 100,000 inhabitants.
Fig. 1. Incidence of first 
primary basal cell carcinomas 
diagnosed in the Nether 
lands. (A) Age-standardized 
period 1973 to 2008 (B) by 
age for 2008. ESR: European 
Standardized Rates.1
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women. During the study period, the total annual num-
ber of newly diagnosed BCC patients rose from 4,179 
to 28,985 (from 1,946 to 13,891 in men and from 2,233 
to 15,094 in women) (Table I and Fig. 2). 
Incidence data by site
In both sexes, BCC occurred approximately ten-fold 
more often in the head and neck region than in other 
regions, such as the trunk and limbs. Men had higher 
BCC rates in the head and neck than women (Fig. 3). 
All body sites displayed increases in incidence rates, 
with the most prominent increase relating to the trunk, 
and the smallest to the lips, whose incidence remained 
close to 1/100,000 person-years. Extrapolating these 
estimates to the Netherlands, between 2000 and 2008, 
yielded estimated increases in incident cases of women 
of 2.8-fold for first BCC on arms, 2.7 for legs and 2.3 
for trunk. For men, the largest increase (3.0) also oc-
curred on the arms, followed by the trunk (2.6) and 
legs (2.4). 
BCC prevalence 
Of the 39,595 patients with a first primary BCC di-
agnosed between 1990 and 2008, 31,414 (79.3%) 
were confirmed to be alive on January 1 2009. Of the 
remaining 8,181 patients, 7,916 (20.0%) had died and 
265 (0.7%) had been lost to follow-up. Of the 31,414 
BCC patients known to be alive on the January 1, 2009, 
14,904 (47.4%) were men and 16,510 (52.6%) women. 
Based on these figures, the overall prevalence in the 
ECR catchment area was estimated to be 1.4% (1.3% 
and 1.5% for men and women, respectively). The over-
all 19-year prevalence for the 65+ age group was 5.4% 
(6.1% for men and 4.9% women). The overall 5-year 
prevalence for this same age group was 2.7% (3.1% and 
2.3% for men and women, respectively) (Table II). 
BCC trend predictions
Trends in BCC incidence for 2010, 2015 and 2020 (es-
timations based on available data for the time period 
2000–2008) showed continuous increases among all age 
groups in both sexes. The predicted rates and absolute 
numbers of BCC cases showed no signs of plateauing 
up to 2020 (Table III). Compared to the observed inci-
dence rates and numbers of cases in 2005, the steepest 
increases by 2020 occurred in the 65+ age group, with 
the exception of the incidence rate in women, which 
increased most steeply in the 35–64 age group. 
Trends in BCC incidence by sub-site, calculated for 
the four most common BCC locations based on data 
from the years 2000–2008, showed continuous increases 
(Table IV). The head and neck area was predicted to be 
the most common site for first primary BCCs for 2010, 
2015 and 2020. By 2020, incidence rates for first primary 
BCCs on the arm in men, are expected to have increased 
more than 2.5-fold from those in 2005. In women, the 
steepest increase in incidence rate is predicted for first 
primary BCCs located on the trunk (2.3-fold). The 
highest increases in predicted BCC numbers by 2020 
are predicted for the arms in men (3.5-fold) and legs in 
women (2.9-fold). 
DISCUSSION
In the last 25 years, the absolute numbers of patients in 
the Netherlands with first, histologically confirmed BCC 
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Fig. 3. Incidence of basal cell carcinoma 
by body site in men (A) and women (B) 
as 3-year moving average European 
Standardized Rates (ESR).
Fig. 2. Estimated absolute numbers of first primary basal cell carcinomas 
(BCC) diagnosed between 1973 and 2008 in the Netherlands.
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increased with about 7-fold in both men and women. 
Furthermore, 1 in 5 men and 1 in 6 women will have 
developed BCC before the age of 85 years. The 19-year 
BCC prevalence in the ECR region was 1.4% and was 
assumed to be representative of the Netherlands as a 
whole. Although the epidemiology of BCC varies geo-
graphically, it is difficult to compare these observations 
with the results of international studies because very few 
cancer registries document BCC and its prevalence has 
not been studied extensively. Nevertheless, other studies 
confirm a trend toward increased incidence of BCC (5, 
15). A recent study in the United States based on a mat-
hematical model found a 31-year prevalence of NMSC 
of nearly 5% (16). Although this reported prevalence was 
about 3 times higher than that in the present study, we 
calculated the prevalence of first primary, histologically 
confirmed BCC cases alone. Moreover, our prevalence 
was not calculated using a statistical model, but with data 
from a population-based cancer registry.
The ECR does not have reliable data on multiple 
BCCs. A recent Dutch prospective population-based 
cohort study involving subjects aged > 55 showed that 
approximately one-third of BCC patients developed 
multiple BCCs during an average follow-up period 
of almost 10 years, of whom 18.1% developed two 
and 12.9% three or more BCCs (9). Taking these 
figures into consideration, the absolute number of 
BCC tumours in the Netherlands since 1990 may be 
as high as 300,000 or more. Moreover, the high risk of 
developing subsequent BCC tumours places a heavy 
burden on the dermatologists’ restricted time, since, 
besides diagnosis and treatment, follow-up is extre-
mely time-consuming. Although recent revisions of 
the BCC guidelines recommend that only high-risk 
patients and/or those with multiple BCCs should be 
followed, this in practice means that almost all BCC 
patients are examined at least once a year for 5 or more 
years after diagnosis (17).
Table II. Five- and 19-year prevalence of basal cell carcinoma 
(BCC) in the Netherlands
Prevalence BCC cases Population Prevalence (%) 
5 years
Total 16,356 2,252,757 0.7
15–34 years  224 535,445 0.04
35–64 years 6,954 979,963 0.7
> 65 years 9,178 342,381 2.7
Men 7,896 1,125,315 0.7
15–34 years  85 274,553 0.03
35–64 years 3,112 497,898 0.6
> 65 years 4,699 151,004 3.1
Women 8,460 1,127,442 0.8
15–34 years  139 260,892 0.05
35–64 years 3,842 482,065 0.8
> 65 years 4,479 191,377 2.3
19 years
Total 31,414 2,252,757 1.4
15–34 years  299 535,445 0.06
35–64 years 12,474 979,963 1.3
> 65 years 18,641 342,381 5.4
Men 14,904 1,125,315 1.3
15–34 years  114 274,553 0.04
35–64 years 5,527 497,898 1.1
> 65 years 9,263 151,004 6.1
Women 16,510 1,127,442 1.5
15–34 years  185 260,892 0.07
35–64 years 6,947 482,065 1.4
> 65 years 9,378 191,377 4.9
Table III. Predicted basal cell carcinoma (BCC) incidence rates (European Standardized Rates per 100,000 person years) and number 
of newly diagnosed tumours in the Netherlands
 
2005
Observed
2010
Expected (95% PI)
2015
Expected (95% PI)
2020
Expected (95% PI)
BCC incidence rate
Men
15–34 years 7.8 9.8 (6.5–12.9)  12.2 (7.1–17.3)  14.6 (7.5–21.7)
35–64 years 136.5 167.6 (155.8–179.3)  198.2 (178.9–217.5)  228.8 (201.5–256.1)
> 65 years 658.1 859.9 (813.6–906.3) 1,067.5 (992.4–1,142.6) 1,275.0 (1,169.7–2,168.8)
All 139.5 162.7 (155.8–169.5)  198.1 (186.9–209.3)  233.5 (217.7–249.2)
Women
15–34 years 14.2 16.1 (11.9–20.3)  18.7 (12.0–25.4)  21.3 (12.0–30.6)
35–64 years 160.7 216.0 (202.9–229.6)  267.4 (246.0–288.8)  318.7 (288.7–348.8)
> 65 years 458.8 587.3 (556.0–618.7)  727.6 (677.5–777.8)  867.9 (797.9–938.0)
All 143.7 153.4 (147.2–159.6)  189.5 (179.4–199.6)  225.6 (211.5–239.8)
Number of cases
Men
15–34 years 163 195 (131–259)  251 (146–357)  306 (157–456)
35–64 years 4,741 6,235 (5,798–6,672) 7,335 (6,616–8,054) 8,604 (7,565–9,642)
> 65 years 6,347 9,584 (9,067–10,101) 14,308 (13,300–15,316) 20,019 (18,350–21,689)
All 11,250 16,011 (15,335–16,687) 21,884 (20,646–23,123) 28,913 (26,943–30,883)
Women
15–34 years 304 320 (237–403)  377 (242–512)  418 (238–598)
35–64 years 5,463 7,846 (7,369–8,323) 9,670 (8,892–10,448) 11,627 (10,514–12,741)
> 65 years 6,074 8,750 (8,301–9,199) 12,252 (11,433–13,072) 16,282 (15,010–17,555)
All 11,841 16,913 (16,248–17,579) 22,288 (21,130–23,447) 28,338 (26,596–30,080)
PI: prediction interval.
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Incidence predictions for the future showed no signs 
of plateauing. Therefore, policymakers and the der-
matologic community should work together to find a 
solution to the ever-growing burden of BCC. Raised 
public awareness may have contributed to the increase 
in BCC detection, but the main causes of the “BCC epi-
demic” are probably ageing and lifestyle changes, such 
as altered patterns of UV exposure. Although earlier 
skin cancer and sun tanning campaigns have increased 
general awareness, they have failed to greatly influence 
our behaviour (because of the so called “knowledge-
behaviour gap”) (18–20). Regulation of the use of 
commercial sunbeds has recently been introduced in 
the Netherlands. Users must now be >18 years of age 
and limits have been placed on UV exposure per visit, 
depending on skin type. However, the use of sunbeds, 
or at least their purchase for home use, could be ban-
ned completely, because indoor tanning represents an 
avoidable risk factor for NMSC (21). Strategies, besides 
prevention that have to be addressed to deal with the 
worsening BCC epidemic, include increasing the derma-
tologist workforce and re-evaluating its organisational 
structure. Investment in supporting professionals, with 
specialised nurses and nurse practitioners, could release 
pressure on dermatologists’ already restricted time. 
Furthermore, technical advances in the management of 
BCC patients may alleviate the pressure on specialised 
care. BCC treatments other than surgery could contri-
bute to a more efficient strategy for dealing with the 
large group of BCC patients. Although new therapies, 
such as photodynamic therapy and treatment with imi-
quimod, have been developed over the past decade, they 
may not be very effective at reducing the BCC burden. 
Currently, no new technological perspectives exist 
that could make BCC care more efficient in the future, 
although promising studies reported the early diagnosis 
of NMSC by fluorescence detection (19, 22).
Strengths and limitations
Extrapolating data from the ECR gave us an impression 
of the annual number of newly diagnosed BCC patients in 
the Netherlands. Nevertheless, demographic factors such 
as socio-economic status, (work-related) UV exposure 
and ethnicity, which can influence BCC development 
(23–25), vary across the country. Indeed, nationwide 
age-specific incidence rates of melanoma standardised to 
the European Standard Population do differ slightly from 
melanoma incidence rates calculated using ECR data. 
However, this difference is relatively small (20.0 versus 
18.8, respectively), although it indicates slight underes-
timation in our extrapolated BCC estimates (26). 
In practice, BCCs may be treated without histological 
verification. BCCs diagnosed non-histologically do not 
appear in the cancer registry. Thus, the absolute numbers 
of first, histologically proven BCCs in the ECR data 
likely underestimates the overall number of cases when 
extrapolated to the Netherlands as a whole. 
Our estimated first primary BCC numbers affecting 
different body sub-sites, are in concordance with the re-
sults of a large Dutch population-based study involving 
more than 11,000 people aged 55 years or more, which 
showed the head and neck area to be the predominant 
site for BCCs, followed by trunk (9). Therefore, body 
Table IV. Predicted basal cell carcinoma (BCC) incidence rates (European Standardized Rates per 100,000 person years) and number 
of newly diagnosed tumours by body site in the Netherlands
 
2005
Observed
2010
Expected (95% PI)
2015
Expected (95% PI)
2020
Expected (95% PI)
BCC incidence rate
Men
Head/Neck  83.1  100.6 (95.7–105.5)  117.2 (109.3–125.1)  133.8 (122.7–145.0)
Trunk  26.2  36.0 (33.0–39.0)  46.8 (42.0–51.5)  57.5 (50.9–64.2)
Arm  10.3  16.2 (14.6–17.9)  21.7 (19.2–24.3)  27.2 (23.7–30.7)
Leg  5.8  7.3 (6.0–8.5)  9.4 (7.4–11.4)  11.5 (8.7–14.3)
Women
Head/Neck  67.2  85.1 (80.9–89.4)  101.0 (94.1–107.8)  116.8 (107.2–126.3)
Trunk  24.6  36.0 (33.3–38.7)  46.8 (42.6–51.0)  57.6 (51.7–63.4)
Arm  9.7  13.9 (12.1–15.7)  24.7 (15.3–21.1)  22.6 (18.6–26.6)
Leg  9.7  13.5 (12.0–15.0)  17.5 (15.1–20.0)  21.5 (18.2–24.9)
Number of cases
Men
Head/Neck 7,188 9,972 (9,487–10,456) 13,221 (12,331–14,111) 17,190 (15,764–18,616)
Trunk 2,350 3,477 (3,189–3,765) 4,945 (4,438–5,451) 6,651 (5,876–7,427)
Arm  907 1,579 (1,419–1,738) 2,339 (2,064–2,614) 3,200 (2,780–3,620)
Leg  500 721 (597–845) 1,048 (824–1,272) 1,454 (1,099–1,809)
Women
Head/Neck 7,131 9,856 (9,388–10,324) 12,576 (11,762–13,390) 15,785 (14,552–17,018)
Trunk 2,273 3,537 (3,279–3,796) 4,797 (4,371–5,222) 6,083 (5,472–6,694)
Arm  974 1,466 (1,280–1,652) 2,083 (1,762–2,403) 2,750 (2,275–3,225)
Leg  989 1,491 (1,327–1,655) 2,113 (1,832–2,394) 2,827 (2,405–3,249)
PI: prediction interval.
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sub-site seems to be adequately registered by the ECR 
with PALgA as a signalling source. To validate the 
prediction methods used, we compared predicted and 
observed BCC incidence rates and numbers of cases in 
the Netherlands for the year 2005 (Table III) (7). The 
rates and numbers of cases of predicted BCC for 2005 
have been re-calculated from those published by de 
Vries et al. (7), because of corrections to the registry 
database, but using the same methodology and based on 
the corrected data for 1989–2000. The observed BCC 
incidence in 2005 was higher than predicted, suggesting 
it increased faster than was estimated based on data 
from 1989–2000 (data not shown). The total number 
of patients diagnosed with a first BCC in 2005 was 
23,091, 21% higher than the predicted total of 19,023 
(95% PI 17,913–20,132). This 21% underestimation 
of the predicted number of cases is likely due to appa-
rent acceleration in the estimated absolute numbers of 
first primary BCCs, starting around the year 2000, as 
shown in Fig. 2. The most probable explanation for this 
relatively steep acceleration in the first primary BCC 
incidence rate and number of cases is changes in medi-
cal practice, i.e. increased (early) detection and more 
BCCs being diagnosed histologically. Other causes may 
include a genuine increase in the incidence of BCCs or 
methodological problems in the prediction models (27). 
The time period on which the predictions were based 
was probably correct, as the increases in incidence have 
been steady over time since 1989. However, our future 
predictions should be interpreted with caution when 
used as guidelines by healthcare organisations, since 
actual BCC rates and numbers of cases will probably 
be much higher than we have estimated. 
The advantage of using prevalence data is that the 
“multiple” BCCs are of less importance. Patients who 
have been diagnosed with one or multiple tumours are 
still only one person. Hence the number of cases is 
informative. Moreover, since we know from previous 
studies that within 5 years after diagnosis about 40% of 
BCC patients develop multiple tumours, we can apply 
these numbers to the prevalence data to get a grasp of 
the problem of multiple BCCs (8, 9).
In conclusion, this observational study shows that 
BCC is a significant healthcare issue and that its burden 
is likely to increase further over time. The incidence and 
prevalence estimates of BCC should urge policymakers 
to provide solutions, since this growing group of BCC 
patients is, and will remain, a serious healthcare problem 
in terms of numbers of patients treated and monitored 
and related healthcare costs. 
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